Synthetic DNA manufacturing: From first experiment to first-in-human
4basebio makes synthetic DNA at every manufacturing level, from research-grade material for your first test to GMP DNA for late-stage trials. One cell-free process, three phase-appropriate grades, made in Cambridge, UK under our MHRA GMP license.
Phase appropriate manufacturing to meet your drug development requirements
OUR GRADES
Choose the phase appropriate manufacturing that fits where your programme is today. Every service level uses the same cell-free manufacturing process, so your DNA never means changing as you programme progresses through the clinic.
DNA FOR FOR NON-CLINICAL USE
Research Use Only
Test it in your own system.
For discovery, in vitro studies, process screening and head-to-head comparison against plasmid.
DNA FOR CLINICAL USE
GMP ClinicalStart
Fast to first-in-human.
For Phase 1/2A trials, plus the toxicology, engineering and stability runs that lead into them.
DNA FOR CLINICAL USE
GMP
Fully validated equipment, process and analytical methods.
For Phase 2B onward and commercial supply, delivered to you or directly to your CDMO.
RESEARCH USE ONLY
Test it in your own system
See how synthetic DNA performs before you commit a programme to it. RUO material is made in our R&D environment on calibrated equipment and ships with a Certificate of Analysis.
Ideal for: discovery, in vitro studies, process screening, and comparison against your current plasmid DNA.
What you get:
• Off-the-shelf constructs for mRNA and AAV production, or your custom sequence from 1 mg to 50 mg
• Certificate of Analysis with every batch
• Research-grade materials, fit-for-purpose testing
GMP CLINICAL START
Fast to first-in-human
GMP ClinicalStart is DNA built for Phase 1/2A trials, where data quality and traceability matter. It is made in accordance with our MHRA GMP licence in dedicated EU GMP Grade D suites, with qualified equipment and defined in-process and release criteria. A streamlined approach keeps early-phase programmes moving.
What you get:
• Qualified product contact equipment and a qualified process
• CoA-inspected materials
• Qualified testing with a wider range of release specifications
• Full QA oversight and release, with a TSE/BSE-free certificate
• A standard quality agreement, with oversight of deviations, OOS results and change control
GMP
Fully validated process and analytical methods
GMP DNA is phase-appropriate material for late-stage clinical manufacture, made under our MHRA GMP licence in dedicated EU GMP Grade D suites. A well-defined process runs under our GMP quality management system with full batch records. It is the same cell-free process as GMP ClinicalStart, so there is no process change as your programme grows.
Ideal for: Phase 2B onward and commercial supply, for mRNA and viral vector manufacture in-house or through your CDMO.
Plan your late Phase supply →
What you get:
• Qualified product contact equipment and a qualified process
• CoA-inspected materials
• Qualified testing with a wider range of release specifications
• Full QA oversight and release, with a TSE/BSE-free certificate
• A standard quality agreement, with oversight of deviations, OOS results and change control
COMPARE GRADES
Phase-appropriate manufacturing
For DNA used to make mRNA or viral vectors.
| SPECIFICATION | RUO | GMP ClinicalStart | GMP |
|---|---|---|---|
| Manufacturing scale | 1 mg – 1 g | Minimum: 25 mg PCV: 5 mg+ |
Minimum: 50 mg PCV: 5 mg+ |
| Environment | R&D | EU GMP Grade D, dedicated | EU GMP Grade D, dedicated |
| Product contact equipment | Calibrated | Qualified | Validated |
| Materials | Research grade | CoA inspected | Qualified |
| Certificate of Analysis | ✓ | ✓ | ✓ |
| Testing and specifications | — | Qualified, wider range | Validated, specific |
| TSE/BSE-free certificate | — | ✓ | ✓ |
| Full QA oversight and release | — | ✓ | ✓ |
| Quality agreement | — | Standard | Standard |
| Deviation, OOS and change control oversight | — | ✓ | ✓ |
For DNA that is itself the active ingredient.
| SPECIFICATION | RUO | GMP ClinicalStart | GMP |
|---|---|---|---|
| Manufacturing scale | 1 mg – 1 g | Minimum: 25 mg PCV: 5 mg+ |
Minimum: 50 mg PCV: 5 mg+ |
| Environment | R&D | EU GMP Grade D, dedicated | EU GMP Grade D, dedicated |
| Product contact equipment | Calibrated | Qualified | Validated |
| Manufacturing process | In development | Qualified | Validated |
| Materials | Research grade | CoA inspected | Fully qualified |
| Certificate of Analysis | ✓ | ✓ | ✓ |
| Testing and specifications | Fit for purpose | Qualified | Validated |
| TSE/BSE-free certificate | ✓ | ✓ | ✓ |
| Full QA oversight and release | — | ✓ | ✓ |
| Quality agreement | — | Standard | Customised |
| Deviation, OOS and change control oversight | — | ✓ | ✓ |
| GMP statement by QP | — | — | On request |
Get the controls your stage needs, without paying for what it doesn't. Use the toggle to switch between DNA as starting material and DNA as drug substance.
WHICH GRADE IS RIGHT FOR YOU?
Find your grade in two questions
Not sure, or your QA team has specific requirements for suppliers? We'll help you choose the right grade for your filing.
One process from bench to late phase
WHY 4BASEBIO
Same DNA, same process.
Our cell-free process stays the same from RUO through GMP. As your programme advances, the controls step up, but the process doesn't change, so you avoid comparability work between phases.
Phase-appropriate, not one-size.
Early programmes get the speed they need. Late-phase programmes get validated methods and analytics packages built around their stage and filing. You pay for what your programme needs.
Licensed and documented.
We manufacture under our MHRA GMP licence in dedicated EU GMP Grade D suites, with full batch records under our GMP quality management system.
Works with your CDMO.
We supply DNA directly to you or to your mRNA or viral vector manufacturer, including material for their engineering runs so they're ready when your GMP batch arrives.
A second source with a different route.
Synthetic DNA can sit alongside your current plasmid supplier, giving you a different manufacturing route as a supply hedge.
Frequently asked questions
-
GMP ClinicalStart is made in accordance with our MHRA GMP licence and is phase-appropriate for Phase 1/2A. If your QA team requires qualified raw materials and validated analytics, that's our GMP grade. We're happy to quote both.
-
GMP ClinicalStart is designed as phase-appropriate material for early clinical trials, and we'll support your filing with documentation.
-
You step up to GMP. It's the same DNA and the same process, with validated product contact equipment and analytics packages matched to your stage.
-
Yes. We can supply material for your CDMO's engineering runs now, so they're ready when your GMP batch arrives.
-
A switch does mean comparability work, so it's worth planning early. Many teams start with us on a new programme or indication. To explore a switch, we can supply RUO and GMP ClinicalStart material for comparability studies first, so your data drives the decision.
-
[CONFIRM: batch scale and capacity commitments]
-
Yes. We expect it for late-phase supply, and we'll schedule it alongside the quality agreement discussion.
-
Late-phase programmes need different testing, so we build analytics packages around your stage and filing. You pay for what your programme needs rather than a fixed package.
-
HQ has been replaced by GMP ClinicalStart for clinical use and RUO for non-clinical use. [CONFIRM: keep this FAQ only if HQ appeared publicly]
Ready to move your DNA forward?
Tell us where your programme is today and we'll recommend the right grade, with a quote to match.